Novo Nordisk's Wegovy Oral Weight Loss Pill Approved, Priced at $149/Month
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Breakthrough in Weight Loss Medications: Novo Nordisk's oral Wegovy was approved by the FDA on December 22, 2025, becoming the first oral GLP-1 medication specifically for obesity, expected to launch in January 2026 at a monthly cost of $149, significantly enhancing patient convenience in treatment options.
- Significant Clinical Trial Results: According to the OASIS 4 clinical trial, participants taking oral Wegovy experienced an average weight loss of 16.6% over 64 weeks, demonstrating comparable efficacy and safety to the injectable version, reinforcing its role in obesity management.
- Improved Patient Accessibility: Oral Wegovy is anticipated to be available through pharmacies and select telehealth providers, lowering barriers for patients, especially in scenarios where insurance coverage is limited, thus aiding more individuals in achieving their weight loss goals.
- Increased Industry Competition: With the launch of oral Wegovy, Novo Nordisk expects to influence pricing and competitive dynamics in the weight loss medication market, particularly against compounded alternatives, potentially attracting more patients seeking effective weight loss solutions.
NVO
$51.47+Infinity%1D
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 52.400
Low
47.00
Averages
57.37
High
70.00
Current: 52.400
Low
47.00
Averages
57.37
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
